Venus Remedies Limited , a prominent player in the Indian pharmaceutical sector, has reported a remarkable financial performance for the second quarter of the fiscal year 2025-26. The company's results showcase significant growth across key financial metrics, indicating a strong market position and operational efficiency, despite challenges faced by its German subsidiary.

Financial Highlights

Venus Remedies has demonstrated robust growth in the second quarter, with its consolidated revenue from operations reaching ₹192.75 crore, a significant jump from ₹137.18 crore in the previous quarter. This represents an impressive 40.5% increase quarter-over-quarter.

Revenue and Profitability

The company's net profit showed substantial growth, rising to ₹20.13 crore from ₹9.60 crore in the preceding quarter, marking a 109.7% increase. For the half-year period, Venus Remedies reported consolidated revenue of ₹329.93 crore with a net profit of ₹29.73 crore.

Subsidiary Performance

Despite the overall positive performance, Venus Remedies' German subsidiary, Venus Pharma GmbH, faces financial challenges. The subsidiary reported:

• Negative net worth of ₹132.10 lakhs
• Revenue of ₹10.61 crore for the quarter
• Net profit of ₹1.21 crore for the quarter

The management expects the subsidiary's financial position to improve by the end of the financial year 2025-26 through proposed financial support and revival strategies.

Additional Notes

• Share application money of ₹2,859.72 lakhs remains pending for allotment in the German subsidiary, as it's not mandatory under German laws.
• Venus Remedies primarily operates in the pharmaceuticals segment.

Conclusion

Venus Remedies' Q2 FY2026 results demonstrate a compelling growth story, with significant increases in revenue and profitability. The company's strong performance in its core operations offsets the challenges faced by its German subsidiary. The management's outlook for the subsidiary's recovery adds a positive note to the company's future prospects in the competitive pharmaceutical landscape.

Venus Remedies , a pharmaceutical company, has announced the opening of a special window for re-lodgement of transfer requests for physical shares. This initiative comes in response to a recent SEBI circular dated July 02, 2023, aimed at facilitating the transfer process for shareholders still holding physical share certificates.

Announcement Details

The company made this announcement through its official social media platforms, including Instagram, Facebook, LinkedIn, and X (formerly Twitter). Venus Remedies has provided links to the notice for shareholders on these platforms, ensuring wide dissemination of this important information.

Regulatory Compliance

In a filing to the stock exchanges, Venus Remedies stated that this announcement is in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's action aligns with SEBI Circular No. SEBI/HO/MIRSD/MIRSD-POD/P/CIR/2023/87 dated July 02, 2023.

Importance for Shareholders

This special window is particularly significant for shareholders who still possess physical share certificates of Venus Remedies. It provides an opportunity for these shareholders to re-lodge their transfer requests, potentially simplifying the process of converting physical shares to electronic form or transferring ownership.

How to Access Information

Shareholders and interested parties can find detailed information about this special window for physical share transfer re-lodgement on Venus Remedies' official social media handles. The company has shared specific links for each platform in their communication to the stock exchanges.

Company Details

Venus Remedies is listed on both the National Stock Exchange of India Ltd. (NSE) and BSE Limited.

This move by Venus Remedies demonstrates the company's commitment to shareholder service and compliance with regulatory requirements. Shareholders holding physical shares are encouraged to take advantage of this special window to address any pending share transfer issues.